Parkside Financial Bank & Trust Acquires 588 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Parkside Financial Bank & Trust lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 78.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,335 shares of the biopharmaceutical company’s stock after purchasing an additional 588 shares during the period. Parkside Financial Bank & Trust’s holdings in Gilead Sciences were worth $82,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Landmark Wealth Management LLC bought a new stake in Gilead Sciences in the 1st quarter worth $30,000. Joseph P. Lucia & Associates LLC bought a new stake in Gilead Sciences in the 1st quarter worth $25,000. TFO TDC LLC bought a new stake in Gilead Sciences in the 1st quarter worth $27,000. Cornerstone Advisory LLC bought a new stake in Gilead Sciences in the 4th quarter worth $34,000. Finally, Mystic Asset Management Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $33,000. Institutional investors own 78.58% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on GILD. Morgan Stanley raised their price target on shares of Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. StockNews.com cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 17th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $63.00 to $74.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 13th. SVB Leerink reaffirmed a “market perform” rating on shares of Gilead Sciences in a research report on Thursday, September 15th. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $73.53.

Gilead Sciences Trading Up 0.4 %

Shares of NASDAQ GILD opened at $63.77 on Friday. Gilead Sciences, Inc. has a 1 year low of $57.17 and a 1 year high of $74.12. The stock has a market cap of $79.93 billion, a P/E ratio of 19.44, a price-to-earnings-growth ratio of 0.61 and a beta of 0.31. The firm has a 50-day moving average of $63.22 and a 200 day moving average of $62.02. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.43 and a quick ratio of 1.27.

Gilead Sciences (NASDAQ:GILDGet Rating) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.07. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $5.88 billion. Gilead Sciences had a net margin of 15.03% and a return on equity of 42.92%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.73 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.92 dividend on an annualized basis and a yield of 4.58%. Gilead Sciences’s dividend payout ratio is currently 89.02%.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.